On February 27, 2021, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the single-dose Janssen/Johnson & Johnson COVID-19 (Ad26.COV2.S) vaccine, a replication-incompetent human adenovirus 26 vector vaccine.
1 As of April 12, 2021, approximately 7 million doses of this vaccine had been administered nationwide.
2,3